Eton Pharmaceuticals, Inc.
NASDAQ:ETON · NASDAQ Global Market
-$0.46 today
Vol 0.58M · Avg 0.43M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ETON · Revenue to Net Income
Key Ratios
Analysis
$86.9M of revenue converted into -$1.5M of net income for the selected period. Gross margin is 55.1% and net margin is -2.2%, showing how much revenue survives after costs and taxes. EPS is $-0.06, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $80.0M +104.9% | $39.0M +23.3% | $31.6M +48.9% | $21.3M -2.7% | $21.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $37.2M +138.5% | $15.6M +47.4% | $10.6M +52.6% | $6.9M +164.3% | $2.6M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $42.7M +82.6% | $23.4M +11.2% | $21.1M +47.1% | $14.3M -25.5% | $19.2M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 53.5% -6.6pp | 60.0% -6.5pp | 66.6% -0.8pp | 67.4% -20.6pp | 88.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $7.8M +138.6% | $3.3M -2.0% | $3.3M -16.9% | $4.0M -35.9% | $6.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $35.8M +57.4% | $22.8M +20.2% | $18.9M +1.9% | $18.6M +28.4% | $14.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $42.7M +64.1% | $26.0M +16.9% | $22.3M -1.4% | $22.6M +9.1% | $20.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $4.0M +252.9% | $1.1M +27.2% | $901.0K -49.2% | $1.8M +284.0% | $462.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | $4.3M +749.5% | -$657.0K -409.9% | $212.0K +102.9% | -$7.2M -385.4% | -$1.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 5.3% +7.0pp | -1.7% -2.4pp | 0.7% +34.8pp | -34.1% -27.3pp | -6.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | $72.0K +102.8% | -$2.6M -117.9% | -$1.2M +85.6% | -$8.3M -452.5% | -$1.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 0.1% +6.7pp | -6.7% -2.9pp | -3.8% +35.1pp | -38.9% -32.0pp | -6.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $4.8M +138.5% | $2.0M +89.2% | $1.1M +11.0% | $955.0K -8.3% | $1.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$4.6M -282.3% | -$1.2M -340.8% | $503.0K +166.1% | -$761.0K -65.4% | -$460.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$4.6M -19.7% | -$3.8M -452.7% | -$689.0K +92.4% | -$9.0M -361.4% | -$2.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -5.7% +4.1pp | -9.8% -7.6pp | -2.2% +40.3pp | -42.4% -33.5pp | -9.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $43.0K +186.7% | $15.0K -93.9% | $247.0K | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$4.6M -20.4% | -$3.8M -308.4% | -$936.0K +89.6% | -$9.0M -361.4% | -$2.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -5.8% +4.0pp | -9.8% -6.8pp | -3.0% +39.5pp | -42.4% -33.5pp | -9.0% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 -13.3% | -$0 -311.0% | -$0 +89.9% | -$0 -363.9% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 -13.3% | -$0 -311.0% | -$0 +89.9% | -$0 -363.9% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $26.9M +3.9% | $25.9M +1.0% | $25.6M +2.0% | $25.1M -0.2% | $25.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $26.9M +3.9% | $25.9M +1.0% | $25.6M +2.0% | $25.1M -0.2% | $25.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
RAPT Therapeutics, Inc.
RAPT
$959.26M
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$881.73M
Omeros Corporation
NASDAQ:OMER
$732.44M
Monopar Therapeutics Inc.
NASDAQ:MNPR
$445.49M
Ocugen, Inc.
NASDAQ:OCGN
$428.23M
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
$305.39M
Bicycle Therapeutics plc
NASDAQ:BCYC
$277.58M
Neumora Therapeutics, Inc. Common Stock
NASDAQ:NMRA
$270.51M
Fulcrum Therapeutics, Inc.
NASDAQ:FULC
$188.85M
ADC Therapeutics S.A.
NYSE:ADCT
$138.00M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ETON generate?
Eton Pharmaceuticals, Inc. (ETON) reported $79.95M of revenue in fiscal 2025.
Is ETON profitable?
Eton Pharmaceuticals, Inc. (ETON) reported -$4,601,000.00 of net income, with a net margin of -5.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.